MedTrace Logo

Phase I/II, Open-Label Trial of Three Monoclonal Antibodies

NCT00219986 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2007-07-18

No results posted yet for this study

Summary

Monoclonal antibody infusions will prevent rebound of viremia in well-suppressed HAART-treated individuals who began therapy during acute and early HIV-1 infection.

Conditions

  • HIV Infections

Interventions

DRUG

Potent HAART during acute or early HIV-1 infection

Sponsors & Collaborators

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Martin Markowitz, MD · Rockefeller University

  • Saurabh Mehandru, MD · Rockefeller University Hosp;ital

  • Anita Shet, MD · Rockefeller University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-10-31
Completion
2005-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219986 on ClinicalTrials.gov